Toll-like receptor 2 and poly(ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE

Nature Immunology

Volumn 10, Issue 9, 2009, Pages 958-964

  Farez, Mauricio F ^a   Quintana, Francisco J ^a   Gandhi, Roopali ^a   Izquierdo, Guillermo ^b   Lucas, Miguel ^b   Weiner, Howard L ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF SEVILLE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

15 KETOCHOLESTANE; 15 KETOCHOLESTENE; 15ALPHA HYDROXICHOLESTENE; GAMMA INTERFERON; INTERLEUKIN 17; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; OXYSTEROL; TOLL LIKE RECEPTOR 2; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE COURSE; DNA DAMAGE; DNA STRAND BREAKAGE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE FUNCTION; GENE INTERACTION; HUMAN; HUMAN CELL; INFLAMMATION; INNATE IMMUNITY; LIPID BLOOD LEVEL; MACROPHAGE; MICROGLIA; MONOCYTE; MOUSE; NERVE DEGENERATION; NEUROINFLAMMATION; NONHUMAN; PRIORITY JOURNAL;

ADULT; AGED; ANIMALS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; HUMANS; HYDROXYCHOLESTEROLS; MALE; MICE; MICE, INBRED NOD; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; POLY(ADP-RIBOSE) POLYMERASES; TOLL-LIKE RECEPTOR 2;

EID: 69049084375     PISSN: 15292908     EISSN: 15292916     Source Type: Journal    
DOI: 10.1038/ni.1775     Document Type: Article

References (32)

1. McFarland, H.F. & Martin, R. Multiple sclerosis: A complicated picture of autoimmunity. Nat. Immunol. 8, 913-919 (2007).
2. Compston, A. & Coles, A. Multiple sclerosis. Lancet 372, 1502-1517 (2008).
3. Rovaris, M. et al. Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol. 5, 343-354 (2006).
4. Lopez-Diego, R.S. & Weiner, H.L. Novel therapeutic strategies for multiple sclerosis - a multifaceted adversary. Nat. Rev. Drug Discov. 7, 909-925 (2008).
5. Trapp, B.D. & Nave, K.A. Multiple sclerosis: An immune or neurodegenerative disorder? Annu. Rev. Neurosci. 31, 247-269 (2008).
6. Trapp, B.D. et al. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338, 278-285 (1998).
7. Balashov, K.E., Comabella, M., Ohashi, T., Khoury, S.J. & Weiner, H.L. Defective regulation of IFNγ and IL-12 by endogenous IL-10 in progressive MS. Neurology 55, 192-198 (2000).
8. + T cells via CD40 ligand. Proc. Natl. Acad. Sci. USA 94, 599-603 (1997).
9. Comabella, M. et al. Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy. J. Clin. Invest. 102, 671-678 (1998).
10. + T cells via CD40-CD40 ligand interactions. J. Neuroimmunol. 125, 134-140 (2002).
11. Karni, A. et al. Innate immunity in multiple sclerosis: Myeloid dendritic cells in secondary progressive multiple sclerosis are activated and drive a proinflammatory immune response. J. Immunol. 177, 4196-4202 (2006).
12. Weiner, H.L. A shift from adaptive to innate immunity: A potential mechanism of disease progression in multiple sclerosis. J. Neurol. 255, 3-11 (2008).
13. Quintana, F.J. et al. Functional immunomics: Microarray analysis of IgG autoantibody repertoires predicts the future response of mice to induced diabetes. Proc. Natl. Acad. Sci. USA 101, 14615-14621 (2004).
14. Robinson, W.H. et al. Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis. Nat. Biotechnol. 21, 1033-1039 (2003).
15. Quintana, F.J. et al. Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proc. Natl. Acad. Sci. USA 105, 18889-18894 (2008).
16. Diestel, A. et al. Activation of microglial poly(ADP-ribose)-polymerase-1 by cholesterol breakdown products during neuroinflammation: A link between demyelination and neuronal damage. J. Exp. Med. 198, 1729-1740 (2003).
17. Basso, A.S. et al. Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis. J. Clin. Invest. 118, 1532-1543 (2008).
18. Suto, M.J., Turner, W.R., Arundel-Suto, C.M., Werbel, L.M. & Sebolt-Leopold, J.S. Dihydroisoquinolinones: The design and synthesis of a new series of potent inhibitors of poly(ADP-ribose) polymerase. Anticancer Drug Des. 6, 107-117 (1991).
19. Jack, C., Ruffini, F., Bar-Or, A. & Antel, J.P. Microglia and multiple sclerosis. J. Neurosci. Res. 81, 363-373 (2005).
20. Nair, A., Frederick, T.J. & Miller, S.D. Astrocytes in multiple sclerosis: A product of their environment. Cell. Mol. Life Sci. 65, 2702-2720 (2008).
21. Smith, K.J. & Lassmann, H. The role of nitric oxide in multiple sclerosis. Lancet Neurol. 1, 232-241 (2002).
22. Charo, I.F. & Ransohoff, R.M. The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med. 354, 610-621 (2006).
23. Kanter, J.L. et al. Lipid microarrays identify key mediators of autoimmune brain inflammation. Nat. Med. 12, 138-143 (2006).
24. Chan, S.M., Ermann, J., Su, L., Fathman, C.G. & Utz, P.J. Protein microarrays for multiplex analysis of signal transduction pathways. Nat. Med. 10, 1390-1396 (2004).
25. Akira, S., Uematsu, S. & Takeuchi, O. Pathogen recognition and innate immunity. Cell 124, 783-801 (2006).
26. Cohen-Armon, M. et al. DNA-independent PARP-1 activation by phosphorylated ERK2 increases Elk1 activity: A link to histone acetylation. Mol. Cell 25, 297-308 (2007).
27. Leoni, V., Lutjohann, D. & Masterman, T. Levels of 7-oxocholesterol in cerebrospinal fluid are more than one thousand times lower than reported in multiple sclerosis. J. Lipid Res. 46, 191-195 (2005).
28. Kutzelnigg, A. et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128, 2705-2712 (2005).
29. Bongarzone, E.R., Pasquini, J.M. & Soto, E.F. Oxidative damage to proteins and lipids of CNS myelin produced by in vitro generated reactive oxygen species. J. Neurosci. Res. 41, 213-221 (1995).
30. Luo, J. et al. Glia-dependent TGF-β signaling, acting independently of the TH17 pathway, is critical for initiation of murine autoimmune encephalomyelitis. J. Clin. Invest. 117, 3306-3315 (2007).
31. Pitt, D., Werner, P. & Raine, C.S. Glutamate excitotoxicity in a model of multiple sclerosis. Nat. Med. 6, 67-70 (2000).
32. Smith, T., Groom, A., Zhu, B. & Turski, L. Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat. Med. 6, 62-66 (2000).